Response Predictors of S-1, Cisplatin, and Docetaxel Combination Chemotherapy for Metastatic Gastric Cancer : Microarray Analysis of Whole Human Genes

• 資料種別: 博士論文
• タイトル: Response Predictors of S-1, Cisplatin, and Docetaxel Combination Chemotherapy for Metastatic Gastric Cancer : Microarray Analysis of Whole Human Genes
• 著者・編者: Kitamura, Shinji; Tanahashi, Toshihito; Aoyagi, Eriko; Nakagawa, Tadahiko; Okamoto, Koichi; Kimura, Tetsuo; Miyamoto, Hiroshi; Mitsui, Yasuhiro; Rokutan, Kazuhito; Muguruma, Naoki; Takayama, Tetsuji
• 著者標目: Kitamura, Shinji; Tanahashi, Toshihito; Aoyagi, Eriko; Nakagawa, Tadahiko; Okamoto, Koichi; Kimura, Tetsuo; Miyamoto, Hiroshi; Mitsui, Yasuhiro; Rokutan, Kazuhito; Muguruma, Naoki; Takayama, Tetsuji
• 出版事項: Karger
• 出版年月日等: 2017-05-17
• 出版年（W3CDTF）: 2017-05-17
• 並列タイトル等: マイクロアレイを用いた切除不能進行胃癌におけるS-1，シスプラチン，ドセタキセル3剤併用化学療法の治療効果予測因子についての検討; Response Predictors of DCS Therapy in Gastric Cancer
• タイトル（掲載誌）: Oncology
• 巻号年月日等（掲載誌）: 93 2
• 掲載巻: 93
• 掲載号: 2
• 掲載ページ: 127-135
• ISSN（掲載誌）: ISSN : 0030-2414; ISSN : 1423-0232
• 授与機関名: 徳島大学
• 授与年月日: 2017-11-30
• 報告番号: 乙第2097号
• 学位: 博士（医学）
• 本文の言語コード: eng
• 件名標目: Gastric cancer; Microarray; Chemotherapy; 胃癌; 化学療法; 効果予測因子; マイクロアレイ; 遺伝子
• 対象利用者: 一般
• 一般注記: Objectives: The aim of this study was to identify biomarkers for predicting the efficacy of docetaxel, cisplatin, and S-1 (DCS) therapy for advanced gastric cancer using microarrays of biopsy specimens before chemotherapy. Methods: Nineteen samples were taken from 19 patients with unresectable metastatic gastric cancer who received DCS as a first-line therapy. Laser capture microdissection was performed, and total cellular RNA was extracted from each microdissected sample. Whole-gene expression was analyzed by microarray, and the difference in mRNA expression observed with the microarrays was confirmed by quantitative real-time PCR. Immunohistochemical staining was performed using clinical tissue sections obtained by endoscopic biopsy. Results: Eleven patients were identified as early responders and 8 patients as nonresponders to DCS therapy. Twenty-nine genes showed significant differences in relative expression ratios between tumor and normal tissues. A classifier set of 29 genes had high accuracy (94.7%) for distinguishing gene expression between 11 early responders and 8 nonresponders. Decreasing the size of the classifier set to 4 genes (PDGFB, PCGF3, CISH, and ANXA5) increased the accuracy to 100%. Expression levels by real-time PCR for validation were well correlated with those 4 genes in microarrays. Conclusion: The genes identified may serve as efficient biomarkers for personalized cancer-targeted therapy.
• 記録形式（IMT）: application/pdf
• オンライン閲覧公開範囲: インターネット公開
• 著作権情報: © 2017 S. Karger AG, Basel
• 関連情報（DOI）: 10.1159/000464329
• 連携機関・データベース: 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• 提供元機関・データベース: 徳島大学 : 徳島大学機関リポジトリ

目次

https://repo.lib.tokushima-u.ac.jp/files/public/11/111015/20190823163926697487/o2097_abstract_review.pdf fulltext

https://repo.lib.tokushima-u.ac.jp/files/public/11/111015/2019082316392718402/o2097_fulltext.pdf fulltext